Trial Profile
A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines.
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 21 Jul 2022
Price :
$35
*
At a glance
- Drugs Lopinavir/ritonavir (Primary) ; Nucleoside reverse transcriptase inhibitors
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- Acronyms IMPAACT-P1083
- 28 Oct 2017 Primary endpoint (Area under curve (AUC) for lopinavir) has been met, according to the results published in the Pediatric Infectious Disease Journal
- 28 Oct 2017 Results published in the Pediatric Infectious Disease Journal
- 21 Sep 2015 Results presented at the Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy and 28th International Congress of Chemotherapy